BR9807473A - Tratamentos de doença relacionados à citocina - Google Patents
Tratamentos de doença relacionados à citocinaInfo
- Publication number
- BR9807473A BR9807473A BR9807473A BR9807473A BR9807473A BR 9807473 A BR9807473 A BR 9807473A BR 9807473 A BR9807473 A BR 9807473A BR 9807473 A BR9807473 A BR 9807473A BR 9807473 A BR9807473 A BR 9807473A
- Authority
- BR
- Brazil
- Prior art keywords
- administration
- compound
- necleoside
- cytokine
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Abstract
Patente de Invenção: <B>"TRATAMENTOS DE DOENçA RELACIONADOS à CITOCINA" <D> Nucleosídeos e outros ce Th1 e Th2 em relação uma à outra, no tratamento de doença. Em um aspecto da invenção, a administração de um nucleosídeo, ou outro composto, reduz a dosagem na qual uma droga primária é administrada. Em um outro aspecto da invenção, uma anormalidade, refletida em resposta aumentada em um grupo de citocinas, é tratada por administração de um necleosídeo, ou outro composto, o qual aumenta a respotro aspecto da invenção, um paciente é profilaticamente tratado por administração de um necleosídeo, ou outro composto, o qual seletivamente reduz a atividade de Th1, sem reduzir significativamente a ado de GTP do paciente até um grau que seletivamente reduz uma das respostas de Th1 ou de TH2, sem significativamente reduzir a outra resposta. As formas de dosagem de liberação contgrolada são parti
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3609497P | 1997-01-17 | 1997-01-17 | |
US4397497P | 1997-04-23 | 1997-04-23 | |
US2858697P | 1997-04-23 | 1997-04-23 | |
US5548797P | 1997-08-12 | 1997-08-12 | |
PCT/US1998/000634 WO1998030223A1 (en) | 1997-01-17 | 1998-01-13 | Cytokine related treatments of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9807473A true BR9807473A (pt) | 2000-03-21 |
Family
ID=27487693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9807473A BR9807473A (pt) | 1997-01-17 | 1998-01-13 | Tratamentos de doença relacionados à citocina |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0998293A4 (pt) |
JP (3) | JP2002515892A (pt) |
KR (1) | KR20000070167A (pt) |
CN (3) | CN1253504A (pt) |
AU (1) | AU736075B2 (pt) |
BR (1) | BR9807473A (pt) |
CA (1) | CA2278158A1 (pt) |
HU (1) | HUP0001526A3 (pt) |
IL (1) | IL130497A0 (pt) |
NO (3) | NO993439L (pt) |
PL (1) | PL336579A1 (pt) |
SI (1) | SI9820003A (pt) |
SK (1) | SK94099A3 (pt) |
WO (1) | WO1998030223A1 (pt) |
YU (1) | YU61598A (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455690B1 (en) * | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN1315862C (zh) | 2000-05-26 | 2007-05-16 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
EP2332574A1 (en) | 2000-08-17 | 2011-06-15 | Tripep Ab | HCV NS3/4A Sequences |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
AU2005247341B2 (en) * | 2004-05-06 | 2008-05-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
US8258104B2 (en) * | 2006-03-14 | 2012-09-04 | Wholesome Biopharm Pty Ltd. | Method and composition for treating allergic diseases |
EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
US10358458B2 (en) * | 2014-09-26 | 2019-07-23 | Riboscience Llc | 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
ES2181673T3 (es) * | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
-
1998
- 1998-01-13 AU AU60238/98A patent/AU736075B2/en not_active Ceased
- 1998-01-13 SK SK940-99A patent/SK94099A3/sk unknown
- 1998-01-13 HU HU0001526A patent/HUP0001526A3/hu unknown
- 1998-01-13 JP JP53124598A patent/JP2002515892A/ja active Pending
- 1998-01-13 PL PL98336579A patent/PL336579A1/xx unknown
- 1998-01-13 KR KR1019997006393A patent/KR20000070167A/ko not_active Application Discontinuation
- 1998-01-13 SI SI9820003A patent/SI9820003A/sl not_active IP Right Cessation
- 1998-01-13 CA CA002278158A patent/CA2278158A1/en not_active Abandoned
- 1998-01-13 BR BR9807473A patent/BR9807473A/pt unknown
- 1998-01-13 EP EP98903474A patent/EP0998293A4/en not_active Withdrawn
- 1998-01-13 WO PCT/US1998/000634 patent/WO1998030223A1/en not_active Application Discontinuation
- 1998-01-13 IL IL13049798A patent/IL130497A0/xx unknown
- 1998-01-13 YU YU61598A patent/YU61598A/sh unknown
- 1998-01-13 CN CN98801801A patent/CN1253504A/zh active Pending
-
1999
- 1999-07-13 NO NO993439A patent/NO993439L/no not_active Application Discontinuation
-
2000
- 2000-07-22 CN CN00121912A patent/CN1312254A/zh active Pending
- 2000-08-29 CN CN00126807A patent/CN1289594A/zh active Pending
- 2000-08-31 NO NO20004329A patent/NO20004329D0/no not_active Application Discontinuation
- 2000-08-31 NO NO20004327A patent/NO20004327D0/no unknown
-
2001
- 2001-05-24 JP JP2001155321A patent/JP2002080490A/ja active Pending
-
2003
- 2003-04-21 JP JP2003115258A patent/JP2004035546A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0998293A1 (en) | 2000-05-10 |
NO993439D0 (no) | 1999-07-13 |
HUP0001526A3 (en) | 2002-10-28 |
NO993439L (no) | 1999-09-13 |
EP0998293A4 (en) | 2002-07-17 |
CN1289594A (zh) | 2001-04-04 |
NO20004327L (no) | 1999-09-13 |
NO20004327D0 (no) | 2000-08-31 |
WO1998030223A1 (en) | 1998-07-16 |
JP2002515892A (ja) | 2002-05-28 |
YU61598A (sh) | 2003-02-28 |
AU6023898A (en) | 1998-08-03 |
IL130497A0 (en) | 2000-06-01 |
NO20004329L (no) | 1999-09-13 |
NO20004329D0 (no) | 2000-08-31 |
PL336579A1 (en) | 2000-07-03 |
JP2004035546A (ja) | 2004-02-05 |
CN1312254A (zh) | 2001-09-12 |
JP2002080490A (ja) | 2002-03-19 |
SK94099A3 (en) | 2001-06-11 |
CA2278158A1 (en) | 1998-07-16 |
KR20000070167A (ko) | 2000-11-25 |
SI9820003A (sl) | 1999-06-30 |
CN1253504A (zh) | 2000-05-17 |
HUP0001526A2 (hu) | 2001-05-28 |
AU736075B2 (en) | 2001-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9908488A (pt) | Composição farmacêutica de topiramato | |
BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
BR9807473A (pt) | Tratamentos de doença relacionados à citocina | |
BR0312286A (pt) | pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae | |
BR9714349A (pt) | L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos | |
BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
AR002974A1 (es) | Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista. | |
BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
BR0008447A (pt) | Métodos de tratamento de distúrbios mitocondriais | |
BR0110420A (pt) | Agonistas muscarìnicos | |
BR9911071A (pt) | Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido | |
BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
BRPI0408999A (pt) | comprimidos prensados de multiparticulados de liberação oral prolongada | |
BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
ES2074698T3 (es) | Composicion oral para el tratamiento de enfermedades intestinales inflamatorias. | |
BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
BR0014155A (pt) | Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino | |
BR0014003A (pt) | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra | |
BR9807112A (pt) | Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato | |
BR0010593A (pt) | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv | |
BR9912218A (pt) | Compostos obtidos de espécies de sálvia possuindo atividade antivirótica | |
DK0909556T3 (da) | Rosaceae-ekstrakt som bradykininantagonist | |
BR9814214A (pt) | Composição com ácido azeláico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |